Loading people...
Alain Horvais is a Partner at Kurma Partners based in Paris, France, where he manages the firm's dedicated Kurma Diagnostics fund. Before joining the venture capital firm in 2015, he accumulated over 20 years of industrial experience, including a decade serving as Research Director at Bio-Rad Paris. His career also encompasses senior administrative and investment roles at AGF Private Equity, which later became Idinvest Partners. At Kurma Partners, which manages over €700 million in assets following a majority stake acquisition by Eurazeo, Horvais directs financial operations and life sciences investments. He has been instrumental in backing portfolio companies such as DNA Script through both the diagnostics and growth opportunities vehicles. Horvais leverages his Doctorate in Molecular Biology and entrepreneurial background to focus on early-stage in vitro diagnostics and medical instrumentation ventures.
Alain Horvais stands as a distinguished Partner at Kurma Partners, a prominent European venture capital firm dedicated to advancing innovation in the life sciences sector. With a profound scientific background and extensive experience in investment, Mr. Horvais plays a pivotal role in identifying, evaluating, and supporting groundbreaking companies that are shaping the future of healthcare. His expertise is instrumental in Kurma Partners' mission to invest in early-stage ventures with high growth potential.
At Kurma Partners, Alain Horvais's investment focus spans a critical range of life science sub-sectors, including novel therapeutics, advanced diagnostics, and innovative medical devices. He is particularly drawn to companies leveraging cutting-edge scientific research to address significant unmet medical needs. His approach is characterized by a deep understanding of biological mechanisms and clinical pathways, allowing him to assess the scientific merit and commercial viability of complex biotechnological and medtech innovations. This rigorous evaluation process ensures that Kurma Partners invests in ventures with robust scientific foundations and clear paths to market.
Mr. Horvais's career trajectory reflects a blend of scientific excellence and strategic investment acumen. Before joining Kurma Partners in 2011, he honed his investment skills as an Investment Director within the life sciences team at CDC Entreprises, which later became part of Bpifrance. In this role, he gained valuable experience in venture capital deal-making and portfolio management. Prior to his venture capital career, Mr. Horvais served as a Project Manager at the French National Research Agency (ANR), where he was involved in funding and overseeing various scientific research projects. This experience provided him with a comprehensive understanding of the research landscape and the challenges faced by early-stage scientific endeavors.
Academically, Alain Horvais holds a PhD in Molecular and Cellular Biology from Paris VI University, a testament to his foundational scientific expertise. He further enriched his research experience as a Post-doctoral fellow at the prestigious Pasteur Institute, contributing to significant advancements in biological understanding. Recognizing the importance of bridging science with business, he also pursued a Master's degree in Management of Biotechnology from ESCP Europe, equipping him with the strategic and financial insights necessary for successful venture capital investment in the life sciences.
Through his work at Kurma Partners, Alain Horvais actively contributes to the growth and success of numerous portfolio companies. While specific individual investments are often a collaborative effort within the firm, his influence is evident in the types of innovative companies Kurma supports—those developing next-generation therapies for challenging diseases, creating more accurate diagnostic tools, and designing advanced medical technologies that improve patient outcomes. His commitment extends beyond capital provision, often involving strategic guidance and mentorship to entrepreneurial teams, helping them navigate the complexities of drug development, regulatory hurdles, and market entry. His vision is to foster a vibrant ecosystem where scientific breakthroughs can translate into tangible health solutions for patients worldwide.
Alain Horvais is a Partner at Kurma Partners, a European venture capital firm specializing in life sciences. He is an experienced investor with a strong scientific background, focusing on early-stage biotech, medtech, and diagnostics companies.
Alain Horvais invests in early-stage life sciences companies, specifically focusing on novel therapeutics, advanced diagnostics, and innovative medical devices. He seeks ventures with strong scientific foundations that address significant unmet medical needs.
Alain Horvais works as a Partner at Kurma Partners, a leading European venture capital firm. Kurma Partners has offices in Paris, France, and Munich, Germany.
